JP2021522862A5 - - Google Patents
Info
- Publication number
- JP2021522862A5 JP2021522862A5 JP2021513004A JP2021513004A JP2021522862A5 JP 2021522862 A5 JP2021522862 A5 JP 2021522862A5 JP 2021513004 A JP2021513004 A JP 2021513004A JP 2021513004 A JP2021513004 A JP 2021513004A JP 2021522862 A5 JP2021522862 A5 JP 2021522862A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- lipid group
- group
- lipid
- conjugate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670319P | 2018-05-11 | 2018-05-11 | |
| US62/670,319 | 2018-05-11 | ||
| PCT/EP2019/062064 WO2019215333A1 (en) | 2018-05-11 | 2019-05-10 | Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522862A JP2021522862A (ja) | 2021-09-02 |
| JP2021522862A5 true JP2021522862A5 (cg-RX-API-DMAC10.html) | 2024-06-07 |
| JP7665509B2 JP7665509B2 (ja) | 2025-04-21 |
Family
ID=66530048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513004A Active JP7665509B2 (ja) | 2018-05-11 | 2019-05-10 | 7’-5’-アルファ-アノマー二環式糖ヌクレオシドを含むオリゴヌクレオチドコンジュゲート |
Country Status (11)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3330276A1 (en) * | 2016-11-30 | 2018-06-06 | Universität Bern | Novel bicyclic nucleosides and oligomers prepared therefrom |
| CA3098623A1 (en) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| WO2021054370A1 (ja) * | 2019-09-18 | 2021-03-25 | 国立大学法人東京医科歯科大学 | 核酸複合体 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP4213883A1 (en) * | 2020-09-16 | 2023-07-26 | Astrazeneca AB | Oligonucleotides conjugated to fatty acids |
| AU2021382146A1 (en) * | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| AU2023404700A1 (en) | 2022-12-02 | 2025-07-10 | Shanghai Argo Biopharmaceutical Co., Ltd. | Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom |
| WO2025217304A1 (en) * | 2024-04-09 | 2025-10-16 | Bio-Rad Laboratories, Inc. | Compositions and methods for detection of contaminant enzymes |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP0500799B1 (en) | 1989-11-16 | 1998-01-14 | Duke University | Particle mediated transformation of animal skin tissue cells |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| AU649074B2 (en) | 1990-10-12 | 1994-05-12 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| AU6044994A (en) | 1993-02-19 | 1994-09-14 | Nippon Shinyaku Co. Ltd. | Glycerol derivative, device and pharmaceutical composition |
| TW404844B (en) | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
| US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
| US6218108B1 (en) | 1997-05-16 | 2001-04-17 | Research Corporation Technologies, Inc. | Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| JP2000325085A (ja) * | 1999-05-21 | 2000-11-28 | Masafumi Matsuo | デュシェンヌ型筋ジストロフィー治療剤 |
| US6653467B1 (en) * | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| AU2003225410A1 (en) * | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| US20080213891A1 (en) | 2004-07-21 | 2008-09-04 | Alnylam Pharmaceuticals, Inc. | RNAi Agents Comprising Universal Nucleobases |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| EA201100811A1 (ru) * | 2006-04-03 | 2012-06-29 | Сантарис Фарма А/С | Фармацевтическая композиция |
| WO2010036698A1 (en) * | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| CA2889044A1 (en) * | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| CA2893801A1 (en) * | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| CN106581043A (zh) * | 2016-10-24 | 2017-04-26 | 佳木斯大学 | 一种适用于杜氏肌营养不良症的药物制剂及其制备方法 |
| EP3330276A1 (en) * | 2016-11-30 | 2018-06-06 | Universität Bern | Novel bicyclic nucleosides and oligomers prepared therefrom |
-
2019
- 2019-05-10 AU AU2019266550A patent/AU2019266550A1/en not_active Abandoned
- 2019-05-10 KR KR1020207034385A patent/KR20210008369A/ko not_active Ceased
- 2019-05-10 US US17/054,724 patent/US20230132377A9/en not_active Abandoned
- 2019-05-10 CA CA3098266A patent/CA3098266A1/en active Pending
- 2019-05-10 BR BR112020022620-3A patent/BR112020022620A2/pt not_active IP Right Cessation
- 2019-05-10 JP JP2021513004A patent/JP7665509B2/ja active Active
- 2019-05-10 WO PCT/EP2019/062064 patent/WO2019215333A1/en not_active Ceased
- 2019-05-10 EP EP19723781.1A patent/EP3790968A1/en active Pending
- 2019-05-10 CN CN201980046260.3A patent/CN112424352A/zh active Pending
- 2019-05-10 SG SG11202010841QA patent/SG11202010841QA/en unknown
-
2020
- 2020-12-04 ZA ZA2020/07564A patent/ZA202007564B/en unknown
-
2024
- 2024-09-10 US US18/830,182 patent/US20250250565A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1964967B (zh) | 路易斯酸介导的环状酯的合成 | |
| CN106795197B (zh) | 改性寡核苷酸及其制备方法 | |
| CA2799501C (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
| JP2022173349A5 (cg-RX-API-DMAC10.html) | ||
| Le Corre et al. | Atherton–Todd reaction: mechanism, scope and applications | |
| JP2898750B2 (ja) | 有機リン化合物をイオウ化するための方法およびそのための試薬 | |
| JP2022513719A5 (cg-RX-API-DMAC10.html) | ||
| JP2020503049A5 (cg-RX-API-DMAC10.html) | ||
| KR102933365B1 (ko) | 뉴클레오티드 조성물 및 이의 방법 | |
| JP6770553B2 (ja) | アルコキシフェニル誘導体、ヌクレオシド保護体およびヌクレオチド保護体、オリゴヌクレオチド製造方法、ならびに、置換基除去方法 | |
| WO2005028494A1 (ja) | 5'-ホスフィチル化モノマーおよびh-ホスホネートオリゴヌクレオチド誘導体の製造方法 | |
| JP2022081575A5 (cg-RX-API-DMAC10.html) | ||
| JP2013138681A5 (cg-RX-API-DMAC10.html) | ||
| JP2022533421A5 (cg-RX-API-DMAC10.html) | ||
| CN102256987A (zh) | 羟甲基膦酸酯、聚氨酯泡沫形成组合物、聚氨酯泡沫以及由其制成的制品的制造方法 | |
| JP2021526017A5 (cg-RX-API-DMAC10.html) | ||
| JP2021506246A5 (cg-RX-API-DMAC10.html) | ||
| JP5749016B2 (ja) | 骨組織を標的としたベクターとしてのヒドロキシ‐ビスホスホン酸誘導体 | |
| EA003091B1 (ru) | Синтез олигонуклеотидов в жидкой фазе | |
| JP2024501288A5 (cg-RX-API-DMAC10.html) | ||
| WO2008141799A1 (en) | Oligophosphoramidates | |
| KR102186143B1 (ko) | 티올 관능기를 포함하는 개질된 올리고뉴클레오티드 및 이를 이용한 핵산의 검출 | |
| JP2018518167A5 (cg-RX-API-DMAC10.html) | ||
| JP2004526737A5 (cg-RX-API-DMAC10.html) | ||
| Krishna et al. | Solid-Phase Synthesis, Thermal Denaturation Studies, Nuclease Resistance, and Cellular Uptake of (Oligodeoxyribonucleoside) methylborane Phosphine–DNA Chimeras |